Breast Cancer Clinical Trial 20203038

[LCID Study Number: 20203038]

A1181: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

This trial will evaluate the efficacy of paclitaxel, trastuzumab, and pertuzumab in eliminating further chemotherapy after surgery in patients with HER2-positive stage II–IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy.

Disease/Condition: Breast Cancer

Department: Hematology and Oncology

Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital; Beverly Hospital; Addison Gilbert Hospital

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421

View NCT ID 04266249 on ClinicalTrials.gov
Protocol #: 20203038
Principal Investigator(s): Corrine Zarwan
Trial Phase: Sponsor Initiated Study Phase 2